Immune to Cancer: The CRI Blog
-
ASCO 2022 Recap: Cancer Immunotherapy Updates
Since the first FDA approval in 2011 to treat cancer patients with checkpoint immunotherapy, doctors have sought… -
FDA Approves New LAG-3 Checkpoint Inhibitor Immunotherapy Combination
Patients with unresectable or metastatic melanoma can now be treated with dual checkpoint blockade targeting the PD-1…
-
Advances in Immunotherapy for Prostate Cancer with Dr. Sumit Subudhi
For Prostate Cancer Awareness Month, CRI spoke with Dr. Sumit Subudhi about advances in immunotherapy for prostate…
-
ASCO20 Update: Considerations for Checkpoint Inhibitors Moving Forward
Results unveiled at ASCO20 increased our understanding of checkpoint immunotherapy in a variety of cancers and circumstances.
-
AACR20 Day 1 Highlights: Breast Cancer, Lung Cancer, and the Microbiome
The first day of the 2020 AACR Annual Meeting shared latest data from immunotherapy clinical trials in…
-
Vaccine-Chemo Combo Shows Promise in Treating Advanced, HPV-Associated Cervical Cancer
Combined with chemotherapy, an HPV-targeting vaccine developed by CRI scientists led to encouraging responses in women with…
-
How Immunotherapy Is Making an Impact in Breast Cancer
We spoke with Rebecca A. Shatsky, MD, about the current treatment landscape for patients with breast cancer,…
-
ASCO19 Recap: Caring for Every Patient, Learning from Every Patient
ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers,…
-
ASCO19 Day 4 Update: Kidney Cancer, Liver Cancer, Stomach Cancer, Esophageal Cancer, and Melanoma
The fourth day at ASCO19 highlighted immunotherapy strategies for patients with kidney cancer, liver cancer, stomach cancer,…